Sun, Dec 28, 2014, 7:16 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Sutor Technology Group Limited Message Board

njsarasotaguy 4 posts  |  Last Activity: Dec 22, 2014 5:25 PM Member since: Aug 31, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • njsarasotaguy by njsarasotaguy Dec 22, 2014 5:25 PM Flag

    If we can close above $5.52 one of these days we may finally see this thing break out of da funk.

  • Reply to

    A Question

    by horcents Dec 10, 2014 12:51 PM
    njsarasotaguy njsarasotaguy Dec 10, 2014 4:07 PM Flag

    July 26, 2013 07:00 AM Eastern Daylight Time
    SALT LAKE CITY--(BUSINESS WIRE)--Lipocine, Inc. (OTCBB:MBARD), a specialty pharmaceutical company, announced today that it has entered into securities purchase agreements with gross proceeds of $38.0 million for the issuance and sale of approximately 6.3 million shares of its common stock at $6.00 per share to institutional investors. The closing of the private placement is subject to customary closing conditions. Proceeds from the private placement will be used primarily to advance Lipocine’s oral testosterone portfolio, LPCN 1021 and LPCN 1111.

    On July 24, 2013, Lipocine successfully completed a reverse merger with Marathon Bar Corp. The combined company will focus solely on the business of Lipocine. Lipocine will trade under the symbol “MBARD” on the OTCBB until on or about August 22, 2013, when it will be quoted under the symbol “LPCN” on the OTCBB.

  • Why does ENDO bother with these acquisitions when they could partner or buy LPCN and get access to the best delivery system for really cheap? They could probably buy LPCN for $200-300 million outright. They recently paid over $ 1.5 Billion for AUXL to access their gels. I just don't get it.

    Endo International plc (ENDP) (ENL.TO), announced today the acquisition of rights to Natesto™ (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation (TRL.TO). Natesto™ was approved by the U.S. Food and Drug Administration (FDA) in May of 2014.

    Under the terms of the agreement Trimel will receive an upfront payment of $25 million and could receive additional payments upon the achievement of certain regulatory and sales milestones. Additionally, Trimel will be responsible for the manufacture and supply of Natesto™ and Endo will pay a tiered supply price for the product. Endo expects the transaction to close in early 2015.

    Sentiment: Strong Buy

  • Reply to

    Patel bought even more yesterday at $5.10

    by buy_n_hold_2001 Nov 26, 2014 8:41 AM
    njsarasotaguy njsarasotaguy Nov 26, 2014 10:00 AM Flag

    This stock has poor liquidity. I think these insider buys are positive. If the stock had better liquidity Patel would probably buy 10,000 shares in one day. Even a 1000 share Mkt order moves the price 20 cents or more sometimes. Yes each purchase is small. However, he keeps buying steadily. That is a good sign.

0.550.00(0.00%)Dec 26 3:42 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Ocwen Financial Corp.
NYSEFri, Dec 26, 2014 4:03 PM EST